LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug ...

TRIUMEQ PD is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in children. TRIUMEQ PD contains the prescription medicines Abacavir, ...

Akums Drugs & Pharmaceuticals Ltd. has announced the launch of the world’s first Lasmiditan dispersible tablets, marking an important step forward in the treatment of acute migraine. The DCGI-approved ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...

Ride-share drivers for app-based companies such as Uber and Lyft have unionized in Massachusetts, forming what state officials and labor leaders said was ‌the first officially recognized organization ...

A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114. Cefpodoxime proxetil (CFPD PRXL) is a third-generation cephalosporin antibiotic with ...

Otsuka is on course to further expand use of its treatment for pulmonary multidrug resistant tuberculosis (MDR-TB) to children. Europe's Committee for Medicinal Products for Human Use (CHMP) has ...

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has announced that the U.S. Food ...

ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV · The FDA approval of ...